Child with Atopic Dermatitis Photo by Eisfelder via Wikimedia Commons A new study shows that treatment with dupilumab significantly restores skin barrier function and reduces inflammation in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Researchers found improvements not only in visible AD lesions but also in clinically unaffected skin, highlighting the systemic nature of the disease. The findings were published in Annals of Allergy, Asthma & Imm

Two reviews from researchers at McMaster University in Hamilton have identified the most effective topical and systemic treatments for...

In a recent study, researchers at National Jewish Health investigated the impact of dupilumab on the vascular barrier function in...

Children with eczema between the ages of six months and six years benefit from treatment with dupilumab, according to the results of a...